Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 8/20 | 0.43 |
| ▸ | MMP2 | P08253 | 8/20 | 0.43 |
| ▸ | MMP3 | P08254 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MMP9 | P14780 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 2/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183913 | 0.80 | MMP13 (0.50) | CA12CA1CA2ADRB2ADRB1 | |
| SCHEMBL20183900 | 0.80 | MMP13 (0.47) | CA12CA1CA2ADRB2ADRB1 | |
| SCHEMBL6200902 | 0.74 | LMNA (0.41) | CA12CA1CA2CA9MMP2 | |
| SCHEMBL5356150 | 0.74 | CHRM2 (0.37) | CA12CA1CA2CA9MMP13 | |
| SCHEMBL20183895 | 0.74 | MMP13 (0.51) | MMP13MMP2MMP3NPSR1ALDH1A1 | |
| SCHEMBL3452817 | 0.74 | CA12 (0.51) | CA12CA1CA2CA9NPSR1 | |
| SCHEMBL20183928 | 0.73 | LMNA (0.50) | ALDH1A1 | |
| SCHEMBL7571307 | 0.73 | APP (0.44) | CA12CA1CA2CA9MMP13 | |
| SCHEMBL7575151 | 0.72 | CASP3 (0.40) | CA12CA1CA2CA9NPSR1 | |
| SCHEMBL5359588 | 0.71 | KMT2A (0.41) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766857-B2 | Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2020-09-08 | — | — | US | disclosed |
| EP-3327000-B1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | UNIV DONGGUK IND ACAD COOP (KR) | 2020-09-02 | — | — | EP | disclosed |
| US-20190071395-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-03-07 | — | — | US | disclosed |
| US-10179764-B2 | Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-01-15 | — | — | US | disclosed |
| US-20180201573-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2018-07-19 | — | — | US | disclosed |
| EP-3327000-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201573-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | LTB4R2, CYSLTR2, LTB4R | CA12 4039/4885CA1 3743/4885CA2 1351/4885 |
| US-10766857-B2 | Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | LTB4R2, CYSLTR2, LTB4R | CA12 4003/4885CA1 3662/4885CA2 1351/4885 |
| US-10179764-B2 | Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | LTB4R2, CYSLTR2, LTB4R | CA12 4003/4885CA1 3662/4885CA2 1351/4885 |
| US-20190071395-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | LTB4R2, CYSLTR2, LTB4R | CA12 4039/4885CA1 3743/4885CA2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.